SCHEMBL4772765

SCHEMBL4772765

CCOC(=O)c1c(C)nc2c(cnn2C)c1-c1cncc(C)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.43
LMNA P02545 3/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
ALDH1A1 P00352 3/20 0.43
MAPT P10636 2/20 0.43
NPSR1 Q6W5P4 2/20 0.43
KDM4E B2RXH2 2/20 0.43
HPGD P15428 2/20 0.43
GAA P10253 2/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
HSD17B10 Q99714 2/20 0.42
GMNN O75496 1/20 0.42
USP2 O75604 1/20 0.42
TP53 P04637 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C9 P11712 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4778962 0.89 LMNA (0.54) SMN1; SMN2LMNAMEN1KMT2AALDH1A1
SCHEMBL4776022 0.83 TSHR (0.43) LMNAMEN1KMT2AALDH1A1MAPT
SCHEMBL27682185 0.79 SIGMAR1 (0.37) MEN1KMT2A
SCHEMBL4775090 0.79 MAPT (0.45) SMN1; SMN2LMNAMEN1KMT2AALDH1A1
SCHEMBL4770110 0.79 LMNA (0.53) SMN1; SMN2LMNAMEN1KMT2AALDH1A1
SCHEMBL4775015 0.78 GLA (0.41) SMN1; SMN2LMNAMEN1KMT2AALDH1A1
SCHEMBL6416344 0.78 ALDH1A1 (0.49) SMN1; SMN2LMNAMEN1KMT2AALDH1A1
SCHEMBL4776213 0.77 MAPT (0.46) SMN1; SMN2LMNAMEN1KMT2AALDH1A1
SCHEMBL4772644 0.77 MEN1 (0.44) SMN1; SMN2LMNAMEN1KMT2AALDH1A1
SCHEMBL6290024 0.77 ALDH1A1 (0.48) SMN1; SMN2LMNAMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7459451-B2 e.g. 1-Ethyl-4-(5-methyl-3-pyridyl)-6-phenyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid; phosphodiesterase (PDE)-IV inhibitor or tumor necrosis factor (TNF)- alpha antagonist; autoimmune diseases, antidepressant, anxiolytic agent; polychondritis, scleroderma, fibrosis, arthritis, Alzheimer's disease ASTELLAS PHARMA INC. (JP) 2008-12-02 US disclosed
EP-1763528-B1 PYRAZOLOPYRIDINE DERIVATIVES ASTELLAS PHARMA INC (JP) 2008-11-26 EP disclosed
US-20060004003-A1 Pyrazolopyridine derivatives ASTELLAS PHARMA INC. (JP) 2006-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004003-A1 Pyrazolopyridine derivatives PDE4A, PDE3B, PDE5A SMN1; SMN2 2957/4885LMNA 3462/4885MEN1 3100/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.